Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights.
Sreekumar S, Montaudon E, Klein D, Gonzalez ME, Painsec P, Derrien H, Sourd L, Smeal T, Marangoni E, Ridinger M. Sreekumar S, et al. Among authors: painsec p. Cancers (Basel). 2024 Sep 25;16(19):3259. doi: 10.3390/cancers16193259. Cancers (Basel). 2024. PMID: 39409880 Free PMC article.
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
Soosainathan A, Iravani M, El-Botty R, Alexander J, Sourd L, Morisset L, Painsec P, Orha R, Nikitorowicz-Buniak J, Pancholi S, Haider S, Dowsett M, Marangoni E, Martin LA, Isacke CM. Soosainathan A, et al. Among authors: painsec p. Cancer Res. 2024 Jan 2;84(1):17-25. doi: 10.1158/0008-5472.CAN-23-0650. Cancer Res. 2024. PMID: 37801608 Free PMC article.
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers.
El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, Lorito N, Sourd L, Huguet L, Dahmani A, Painsec P, Derrien H, Vacher S, Masliah-Planchon J, Raynal V, Baulande S, Larcher T, Vincent-Salomon A, Dutertre G, Cottu P, Gentric G, Mechta-Grigoriou F, Hutton S, Driouch K, Bièche I, Morandi A, Marangoni E. El-Botty R, et al. Among authors: painsec p. Nat Commun. 2023 Jul 14;14(1):4221. doi: 10.1038/s41467-023-40022-5. Nat Commun. 2023. PMID: 37452026 Free PMC article.
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance.
Montaudon E, Nikitorowicz-Buniak J, Sourd L, Morisset L, El Botty R, Huguet L, Dahmani A, Painsec P, Nemati F, Vacher S, Chemlali W, Masliah-Planchon J, Château-Joubert S, Rega C, Leal MF, Simigdala N, Pancholi S, Ribas R, Nicolas A, Meseure D, Vincent-Salomon A, Reyes C, Rapinat A, Gentien D, Larcher T, Bohec M, Baulande S, Bernard V, Decaudin D, Coussy F, Le Romancer M, Dutertre G, Tariq Z, Cottu P, Driouch K, Bièche I, Martin LA, Marangoni E. Montaudon E, et al. Among authors: painsec p. Nat Commun. 2020 Aug 13;11(1):4053. doi: 10.1038/s41467-020-17697-1. Nat Commun. 2020. PMID: 32792481 Free PMC article.
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F, El Botty R, Lavigne M, Gu C, Fuhrmann L, Briaux A, de Koning L, Dahmani A, Montaudon E, Morisset L, Huguet L, Sourd L, Painsec P, Chateau-Joubert S, Larcher T, Vacher S, Melaabi S, Salomon AV, Marangoni E, Bieche I. Coussy F, et al. Among authors: painsec p. J Hematol Oncol. 2020 Feb 22;13(1):13. doi: 10.1186/s13045-020-0846-y. J Hematol Oncol. 2020. PMID: 32087759 Free PMC article.
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Coussy F, El-Botty R, Château-Joubert S, Dahmani A, Montaudon E, Leboucher S, Morisset L, Painsec P, Sourd L, Huguet L, Nemati F, Servely JL, Larcher T, Vacher S, Briaux A, Reyes C, La Rosa P, Lucotte G, Popova T, Foidart P, Sounni NE, Noel A, Decaudin D, Fuhrmann L, Salomon A, Reyal F, Mueller C, Ter Brugge P, Jonkers J, Poupon MF, Stern MH, Bièche I, Pommier Y, Marangoni E. Coussy F, et al. Among authors: painsec p. Sci Transl Med. 2020 Feb 19;12(531):eaax2625. doi: 10.1126/scitranslmed.aax2625. Sci Transl Med. 2020. PMID: 32075943 Free PMC article.
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F, Lavigne M, de Koning L, Botty RE, Nemati F, Naguez A, Bataillon G, Ouine B, Dahmani A, Montaudon E, Painsec P, Chateau-Joubert S, Laetitia F, Larcher T, Vacher S, Chemlali W, Briaux A, Melaabi S, Salomon AV, Guinebretiere JM, Bieche I, Marangoni E. Coussy F, et al. Among authors: painsec p. Theranostics. 2020 Jan 1;10(4):1531-1543. doi: 10.7150/thno.36182. eCollection 2020. Theranostics. 2020. PMID: 32042320 Free PMC article.
A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F, de Koning L, Lavigne M, Bernard V, Ouine B, Boulai A, El Botty R, Dahmani A, Montaudon E, Assayag F, Morisset L, Huguet L, Sourd L, Painsec P, Callens C, Chateau-Joubert S, Servely JL, Larcher T, Reyes C, Girard E, Pierron G, Laurent C, Vacher S, Baulande S, Melaabi S, Vincent-Salomon A, Gentien D, Dieras V, Bieche I, Marangoni E. Coussy F, et al. Among authors: painsec p. Int J Cancer. 2019 Oct 1;145(7):1902-1912. doi: 10.1002/ijc.32266. Epub 2019 Apr 4. Int J Cancer. 2019. PMID: 30859564